Abstract
The nature of the dyslipidemia associated with diabetes mellitus is complex and is the major risk factor for atherosclerosis and coronary artery disease. Aim of this study was to assess the effect of glycemic control, achieved by metformin, glibenclamide and insulin, on lipid profile in type 2 diabetic patients. One hundred and sixty-five type 2 diabetes mellitus patients were classified into good glycemic control (Group I) and poor glycemic control (Group II) on the basis of their blood HbA1c values. The Group II was characterized with high serum triglyceride (190.46 ± 15.20 mg/dl), total cholesterol (175.3 ± 6.31 mg/dl) as well as high LDL-cholesterol (109.0 ± 5.88 mg/dl). Significant correlations were evident between HbA1c and dyslipidemia, particularly serum TG (r = 0.28, P < 0.05), and between HbA1c and total cholesterol (r = 0.310, P < 0.05). Better glycemic control and improved dyslipidemia were observed in patients on combination therapy of metformin plus glibenclamide.
Similar content being viewed by others
References
Gomes M, Gianella D, Faria M, Tambascia M, Fonseca R, Réa R, Macedo G, Filho J, Schmid H, Bittencourt A, Cavalcanti S, Rassi N, Pedrosa H, Atala S. Prevalence of Type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multi-center study in Brazil. Rev Diabet Stud. 2006;3(2):82–7.
Rizvi A, Sanders MB. Assessment and monitoring of glycemic control in primary diabetes care: monitoring techniques, record keeping, meter downloads, tests of average glycemia, and point-of-care evaluation. J Am Acad Nurse Pract. 2006;18:11–21.
Mooradian AD. Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. Arch Intern Med. 2003;163:33–40.
Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27:1496–504.
WHO. WHO model list of essential medicines. 16th ed. World Health Organization; 2010. p. 24. Available at www.who.int/medicines/publications/essentialmedicines/.
Pfutzner A, Schondorf T, Tschope D, Lobmann R, Merke J, Muller J, Lehmann U, Fuchs W, Forst T. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther. 2011;13(6):637–43.
Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147:386–99.
Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist M, Efendic S, Moller DE, Thorell A, Goodyear LJ. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002;51:2074–81.
Zander R, Lang W, Wolf HU. The determination of haemoglobin as cyanhaemiglobin or as alkaline haematin D-575. Comparison of method-related errors. J Clin Chem Clin Biochem. 1989;27(4):185–9.
Metus P, Ruzzante N, Bonvicini P, Meneghetti M, Zaninotto M, Plebani M. Immunoturbidimetric assay of glycated hemoglobin. J Clin Lab Anal. 1999;13(1):5–8.
Bianchi C, Penno G, Pancani F, Civitelli A, Piaggesi A, Caricato F, Pellegrini G, Del Prato S, Miccoli R. Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes. Diabetes Res Clin Pract. 2003;78(2):246–53.
Betteridge DJ. Diabetic dyslipidaemia. Eur J Clin Invest. 1999;29(2):12–6.
Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am. 2006;35:491–510.
Feleke Y, Enquselassie F. An assessment of the health care system for diabetes in Addis Ababa, Ethiopia. Ethiop J Health Dev. 2005;19(3):203–10.
Kannel W, Gordon T, Castelli W. Obesity, lipids, and glucose intolerance. The Framingham Study. Atherosclerosis. 1993;102(1):63–7.
Siraj ES, Seyoum B, Saenz C, Abdulkadir J. Lipid and lipoprotein profiles in Ethiopian patients with diabetes mellitus. Metabolism. 2007;55(6):706–10.
Abdel-Gayoum AG. The effect of glycemic control in type 2 diabetic patients with diabetes-related dyslipidemia. Saudi Med J. 2004;25(2):207–11.
Ceriello A, Kumar S, Piconi L, Esposito K, Giugliano D. Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care. 2007;30(3):649–54.
Guerci B, Böhme P, Kearney-Schwartz A, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab (Paris). 2001;27:436–47.
Hirano T, Mamo JC, Furukawa S, Nagano S, Takahashi T. Effect of acute hyperglycemia on plasma triglyceride concentration and triglyceride secretion rate in non fasted rats. Diabetes Res Clin Pract. 1990;9(3):31–8.
Fujita Y, Fukushima M, Suzuki H, Taniguchi A, Nakai Y, Kuroe A, Yasuda K, Hosokawa M, Yamada Y, Inagaki N, Seino Y. Short-term intensive glycemic control improves vibratory sensation in type 2 diabetes. Diabetes Res Clin Pract. 2008;80(1):e16–9.
U.K. Prospective Diabetes Study. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care. 1997;20:1683–1687.
Mohammadi H, Abdelouahed E-M, Hassar M, Bouchrif B, Qarbal B, Dahbi F, Hilal L, Ghalim N. Glycaemic control, HbA1c, and lipid profile in children with type 1 diabetes mellitus. Eur J Sci Res. 2009;29(2):289–94.
Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150–9.
Nikkilä EA, Taskinen MR. Lipoprotein lipase of adipose tissue and skeletal muscle in human obesity: response to glucose and to semistarvation. Metabolism. 1981;30(8):810–7.
Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:1225–36.
Khan AH. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. Acta Diabetol. 2007;44(4):193–200.
Schwartz SL. Diabetes and dyslipidaemia. Diabetes Obes Metab. 2006;8(4):355–64.
Cook MN, Girman CJ, Stein PP, et al. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control continues to deterio-rate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005;28:995–1000.
Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65(3):385–411.
Wiernsperger NF, Bailey CJ. The antihyperglycemic effect of metformin: therapeutic and cellular mechanisms. Drugs. 1999;58:31–9.
Collier CA, Bruce CR, Smith AC, Lopaschuk G, Dyck DJ. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am J Physiol Endocrinol Metab. 2006;291(1):E182–9. doi:10.1152/ajpendo.00272.2005.
Acknowledgments
The financial support from the Addis Ababa University, Ethiopia is dually acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mullugeta, Y., Chawla, R., Kebede, T. et al. Dyslipidemia Associated with Poor Glycemic Control in Type 2 Diabetes Mellitus and the Protective Effect of Metformin Supplementation. Ind J Clin Biochem 27, 363–369 (2012). https://doi.org/10.1007/s12291-012-0225-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12291-012-0225-8